Our Science

As a global biopharmaceutical company with a focus on innovation and specialty care, we have the ambition to build a robust, valuable, and sustainable portfolio of medicines to meet patients and their healthcare teams’ needs.


Neuroendocrine tumors, kidney, liver, pancreatic, medullary thyroid cancer, prostate and breast cancer

Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of people living with cancer.

Read more


Neurodegenerative, rare neuroinflammatory and movement disorders

With over 25 years of research, development and commercial experience in neuroscience, we are fully committed to improving health outcomes for patients suffering from debilitating neurological disorders.

Read more

Rare disease

Bone disorders, growth disorders, rare cancers and rare neurogenetic disorders

Working with the rare disease community, we strive to better understand the challenges faced by those living with rare diseases and their families, and then use our expertise to help address them.

Read more


At Ipsen, our research decisions are guided by patient outcomes.

Emphasizing a culture of open innovation, we focus our R&D efforts on accelerating prioritized internal projects while actively sourcing external assets.

Read more

Find an Ipsen Clinical Trial

Read more

Learn more about our Investigator Sponsored Studies

We supports independent research relating to disease areas of interest to Ipsen to advance research and enhance disease understanding

Read more
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023